Key points are not available for this paper at this time.
Design
Review
Highlights ongoing unmet need in antiplatelet development; leaves open optimal strategies from prospective trials.
An improved understanding of the underlying mechanisms of platelet activation and thrombogenesis has led to the discovery of new antiplatelet agents. Various clinical studies have investigated the effectiveness of these new agents in comparison with ‘traditional’ antiplatelet drugs. The problem with this approach is that enhanced antiplatelet activity may result in excessive bleeding complications. Consequently, the challenge is to ascertain the fine balance between optimal efficacy and safety for future antiplatelet drugs and their combinations.
No takes yet. Share an insight, caveat, or question.
Kuzniatsova et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: